MX2018006875A - Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab. - Google Patents

Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.

Info

Publication number
MX2018006875A
MX2018006875A MX2018006875A MX2018006875A MX2018006875A MX 2018006875 A MX2018006875 A MX 2018006875A MX 2018006875 A MX2018006875 A MX 2018006875A MX 2018006875 A MX2018006875 A MX 2018006875A MX 2018006875 A MX2018006875 A MX 2018006875A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
aqueous pharmaceutical
antibody avelumab
antibody
avelumab
Prior art date
Application number
MX2018006875A
Other languages
English (en)
Inventor
Del Rio Alessandra
Rinaldi Gianluca
FRATARCANGELI Silvia
Weigandt Markus
Voss Senta
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54838201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018006875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2018006875A publication Critical patent/MX2018006875A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una formulación de anticuerpo anti-PD-L1 novedosa. En particular, la invención se refiere a una formulación farmacéutica acuosa del anticuerpo anti-PD-L1 Avelumab.
MX2018006875A 2015-12-07 2016-12-05 Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab. MX2018006875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15198233 2015-12-07
PCT/EP2016/002040 WO2017097407A1 (en) 2015-12-07 2016-12-05 Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab

Publications (1)

Publication Number Publication Date
MX2018006875A true MX2018006875A (es) 2018-11-09

Family

ID=54838201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006875A MX2018006875A (es) 2015-12-07 2016-12-05 Formulacion farmaceutica acuosa que comprende el anticuerpo anti receptor de muerte programada l1 (pd-l1) avelumab.

Country Status (35)

Country Link
US (2) US11058769B2 (es)
EP (2) EP3747466A1 (es)
JP (1) JP6925337B2 (es)
KR (1) KR20180085801A (es)
CN (1) CN108367072B (es)
AR (1) AR107014A1 (es)
AU (1) AU2016368099C1 (es)
BR (1) BR112018010211A2 (es)
CA (1) CA3007481C (es)
CL (1) CL2018001488A1 (es)
CO (1) CO2018005525A2 (es)
CY (1) CY1123358T1 (es)
DK (1) DK3386541T3 (es)
EA (1) EA201891339A1 (es)
ES (1) ES2823279T3 (es)
HK (1) HK1257781A1 (es)
HR (1) HRP20201573T1 (es)
HU (1) HUE050811T2 (es)
IL (1) IL259563B (es)
LT (1) LT3386541T (es)
MX (1) MX2018006875A (es)
MY (1) MY195681A (es)
NZ (1) NZ743964A (es)
PE (1) PE20181400A1 (es)
PH (1) PH12018500894A1 (es)
PL (1) PL3386541T3 (es)
PT (1) PT3386541T (es)
RS (1) RS61029B1 (es)
SA (1) SA518391743B1 (es)
SG (1) SG11201804758QA (es)
SI (1) SI3386541T1 (es)
TW (1) TWI630917B (es)
UA (1) UA123270C2 (es)
WO (1) WO2017097407A1 (es)
ZA (1) ZA201804534B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6138813B2 (ja) * 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体及びその使用
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
AU2016233495B2 (en) 2015-03-13 2022-02-24 Cytomx Therapeutics, Inc Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
PT3386541T (pt) 2015-12-07 2020-10-12 Merck Patent Gmbh Formulação farmacêutica aquosa compreendendo o anticorpo anti-pd-1 avelumab
PE20190510A1 (es) 2016-06-13 2019-04-10 I Mab Anticuerpos anti-pd-l1 y usos de los mismos
CN109843324A (zh) 2016-10-06 2019-06-04 辉瑞公司 用于治疗癌症的avelumab用药方案
BR112019018401A2 (pt) * 2017-03-06 2020-04-07 Merck Patent Gmbh formulação aquosa de anticorpo anti-pd-l1
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
CN114632150B (zh) * 2017-11-02 2023-12-19 正大天晴药业集团股份有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
WO2020020307A1 (en) 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
WO2020060183A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 트라스투주맙 항체 안정화 액체 제제
US20230287122A1 (en) * 2018-11-29 2023-09-14 Harbour Biomed Therapeutics Limited Anti-pd-l1 antibody preparation
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
TWI761869B (zh) * 2019-06-25 2022-04-21 大陸商信達生物製藥（蘇州）有限公司 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
CN111420049A (zh) * 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
JP2023506629A (ja) * 2019-12-13 2023-02-17 サムスン バイオエピス カンパニー リミテッド 安定した抗ｐｄ－１抗体の薬剤学的製剤
EP4362984A1 (en) 2021-07-02 2024-05-08 Yale University Compositions and methods for treating cancers
WO2023034864A1 (en) 2021-08-31 2023-03-09 Yale University Compositions and methods for treating cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
SI2264043T1 (en) 2005-09-02 2018-01-31 Glycomimetics, Inc. HETEROBIFUNCTIONAL PAN-SELECTINE INHIBITORS
CN101584858A (zh) 2005-12-20 2009-11-25 布里斯托尔-迈尔斯斯奎布公司 稳定蛋白质制剂
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
HUE034832T2 (hu) * 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
SG182304A1 (en) * 2009-12-29 2012-08-30 Hoffmann La Roche Antibody formulation
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
LT2691112T (lt) * 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
JP6138813B2 (ja) * 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体及びその使用
CN104169299B (zh) * 2012-01-23 2018-06-05 瑞泽恩制药公司 含抗Ang-2 抗体的稳定化制剂
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
SI3049441T1 (sl) 2013-09-27 2020-03-31 F. Hoffmann-La Roche Ag Formulacije protiteles proti PD-L1
CA2926588C (en) * 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
KR20170003692A (ko) * 2014-05-15 2017-01-09 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항암제의 조합물을 사용한 폐암의 치료
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
NZ733854A (en) 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
US10945994B2 (en) 2015-05-14 2021-03-16 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
WO2016205277A1 (en) 2015-06-16 2016-12-22 Merck Patent Gmbh Pd-l1 antagonist combination treatments
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
PT3386541T (pt) 2015-12-07 2020-10-12 Merck Patent Gmbh Formulação farmacêutica aquosa compreendendo o anticorpo anti-pd-1 avelumab
BR112019018401A2 (pt) 2017-03-06 2020-04-07 Merck Patent Gmbh formulação aquosa de anticorpo anti-pd-l1

Also Published As

Publication number Publication date
SI3386541T1 (sl) 2020-11-30
US11058769B2 (en) 2021-07-13
HK1257781A1 (zh) 2019-10-25
LT3386541T (lt) 2020-10-26
AU2016368099C1 (en) 2023-10-12
AR107014A1 (es) 2018-03-14
CO2018005525A2 (es) 2018-08-10
CA3007481C (en) 2024-01-30
JP6925337B2 (ja) 2021-08-25
PE20181400A1 (es) 2018-09-07
CA3007481A1 (en) 2017-06-15
HRP20201573T1 (hr) 2020-12-11
EP3747466A1 (en) 2020-12-09
IL259563A (en) 2018-07-31
AU2016368099B2 (en) 2023-03-09
PH12018500894A1 (en) 2018-11-05
ZA201804534B (en) 2020-11-25
RS61029B1 (sr) 2020-12-31
IL259563B (en) 2021-05-31
AU2016368099A1 (en) 2018-07-19
CY1123358T1 (el) 2021-12-31
NZ743964A (en) 2023-03-31
EA201891339A1 (ru) 2019-01-31
SG11201804758QA (en) 2018-07-30
EP3386541A1 (en) 2018-10-17
PL3386541T3 (pl) 2021-04-06
HUE050811T2 (hu) 2021-01-28
US20180369377A1 (en) 2018-12-27
TWI630917B (zh) 2018-08-01
CL2018001488A1 (es) 2018-09-14
UA123270C2 (uk) 2021-03-10
JP2018536676A (ja) 2018-12-13
EP3386541B1 (en) 2020-07-08
DK3386541T3 (da) 2020-09-28
CN108367072B (zh) 2022-12-27
TW201725051A (zh) 2017-07-16
BR112018010211A2 (pt) 2019-02-05
SA518391743B1 (ar) 2022-12-01
US20210100903A1 (en) 2021-04-08
CN108367072A (zh) 2018-08-03
KR20180085801A (ko) 2018-07-27
ES2823279T3 (es) 2021-05-06
MY195681A (en) 2023-02-03
WO2017097407A1 (en) 2017-06-15
PT3386541T (pt) 2020-10-12

Similar Documents

Publication Publication Date Title
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
IL257062A (en) New anti-pd-1 antibodies
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
MY191581A (en) Anti-pd-1 antibodies
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
HK1256414A1 (zh) 新穎醣類抗體、醫藥組成物及其用途
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
EP3512885A4 (en) ANTI-PD-1 ANTIBODY
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
IN2014MU01248A (es)
IN2014CH00840A (es)
EA201791716A1 (ru) Фармацевтический состав
EP3498839A4 (en) ANTI-PD-1 ANTIBODIES
HUE054716T2 (hu) Anti-EGFR-t tartalmazó gyógyászati készítmény
MX2016008884A (es) Formas solidas de tenofovir.
TH1501005391A (th) องค์ประกอบทางเภสัชกรรมแบบผงละเอียด
NZ743656A (en) Methods of treating a tauopathy